权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pathogen and Microbiome Temporal Changes During Resolution of HAP

HAP 消退过程中病原体和微生物组的时间变化

基本信息

批准号：
10097985
负责人：
ALAN R HAUSER
金额：
$ 49.82万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-17 至 2022-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10097985
关键词：
Acinetobacter Acinetobacter baumannii Age Antibiotic Therapy Antibiotic susceptibility Antibiotics Bacteria Bronchoalveolar Lavage Bronchoalveolar Lavage Fluid Clinical Communities Complication Computer Models DNA Data Data Analyses Data Set Development Disease Disease Outcome Elements Failure Functional disorder Funding Opportunities Generations Genetic Genome Genomics Goals Immunosuppression Infection Infrastructure Institution Instruction Intervention Knowledge Lung Mechanical ventilation Microbe Microbiology Modeling Observational Study Outcome Patient Isolators Patients Pattern Play Pneumonia Process Pseudomonas aeruginosa Recovery Research Research Project Grants Resolution Resources Role Shotguns Specimen Systems Biology Testing Virus Work advanced system base biosignature clinical predictors clinical risk comorbidity fungus genome-wide high risk improved large datasets lung microbiome metagenomic sequencing microbial microbiome microbiome components mortality novel therapeutic intervention novel therapeutics pathogen pathogen genome pneumonia treatment response success transcriptome transcriptomics ventilator-associated pneumonia viral RNA

项目摘要

Project Summary Project 2: Pathogen and Microbiome Temporal Changes During Resolution of HAP Severe pneumonia is a dreaded complication among mechanically ventilated patients and is associated with high rates of mortality. To better understand these challenging infections, we propose to develop the Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center. The overall goal of SCRIPT Research Project 2 is to create a computational model based on microbial biosignatures that predicts clinical failure in patients with ventilator-associated pneumonia. Specific pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii are particularly problematic in ventilator-associated pneumonia and are associated with clinical failure rates as high as 50%, even in patients treated with appropriate antibiotic therapy. For this reason, we will focus on pneumonia caused by these pathogens. Work from our group and others has shown that strains of these bacteria differ dramatically in their ability to cause severe infections. Furthermore, emerging evidence indicates that alterations in the pulmonary microbiome induced by pathogens or by the antibiotics used to treat them may contribute to poor clinical outcomes. We hypothesize that specific genetic biosignatures of P. aeruginosa and Acinetobacter baumannii and other spp. and particular alterations to the pulmonary microbiome are associated with clinical failure in patients with HAP. To test this hypothesis, we will perform the following aims: Aim 1. We will identify genetic biosignatures of P. aeruginosa and A. baumannii strains associated with poor clinical responses in patients with severe pneumonia. Aim 2. We will identify pulmonary microbiome constituents (bacteria, viruses, and fungi) and longitudinal microbiome patterns associated with poor clinical responses in patients with severe pneumonia. Aim 3. Generate a computational model that integrates pathogen genome, pathogen transcriptome, and microbiome components to predict the clinical response in severe pneumonia caused by P. aeruginosa or A. baumannii. The data we generate will be used in an iterative manner to create and optimize a computational model that identifies patients at risk for clinical failure based upon the microbiology of their pneumonia. Highly discriminatory microbiological biosignatures for clinical failure will be further examined to determine whether they play a causal role in the progression of pneumonia.

项目2:HAP分辨率期间病原体和微生物组的时间变化